EP Patent

EP4691567A2 — Jak1 pathway inhibitor for use in the treatment of chronic lung allograft dysfunction

Assigned to Incyte Corp · Expires 2026-02-11 · 0y expired

What this patent protects

This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating chronic lung allograft dysfunction such as, e.g., bronchiolitis obliterans syndrome.

USPTO Abstract

This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating chronic lung allograft dysfunction such as, e.g., bronchiolitis obliterans syndrome.

Drugs covered by this patent

Patent Metadata

Patent number
EP4691567A2
Jurisdiction
EP
Classification
—
Expires
2026-02-11
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.